The other authors declare that they have no conflict of interest. Wichtigste unerwünschte Arzneimittelwirkung (UAW) [2] Die Statine verursachen weniger oft UAW als die meisten anderen Lipid-senkenden Arzneimitteln und sind i. Can lower your risk of heart attack, stroke, and death, particularly if you have diabetes, high blood pressure, obesity, or a history of smoking. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. High potency statins allow LDLc reduction > 50% and for that intensity, a similar clinical benefit is assumed [3]. Patients were eligible for inclusion in this study if they were 18 years of age or older with previous ASCVD at inclusion in the registry. 2019 May 15;123(10):1565-1571. doi: 10.1016/j.amjcard.2019.02.019. 2011;8:721–5. Only those subjects under continuous treatment with atorvastatin (n = 243) or rosuvastatin (n = 164) were included in this analysis (Fig. Subjects with recurrent ASCVD presented higher pre-treatment concentration of non-HDLc than those subjects without recurrences during the follow-up. All authors read and approved the final manuscript. Evidence from genetic, epidemiologic, and clinical studies. Statins such as Lipitor (atorvastatin) can cause digestive problems, blood sugar problems, muscle aches and stiffness, muscle injury, kidney damage, or liver damage. Participants were divided according to the type of statins recorded at the time of inclusion in the registry. Among them, 176 took atorvastatin at the time of inclusion in the registry and 111 subjects rosuvastatin. Among atorvastatin or rosuvastatin users, 89 recurrences of ASCVD were recorded (21.9%), of which 85.4% were coronary. 2). This observational and retrospective analysis of ASCVD recurrences does not find appreciable clinical differences between high doses of rosuvastatin and atorvastatin, and supports their use as clinically equivalent in secondary prevention of ASCVD. Statins include atorvastatin (Lipitor), fluvastatin (Lescol XL), lovastatin (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor, Ezallor) and simvastatin (Zocor, FloLipid). Privacy After treatment, HDLc has higher in the rosuvastatin group, and the differences in total cholesterol and non-HDLc were reduced to a level at which they did not reach statistical significance any more (Table 1). Epub 2019 Feb 23. 2006;355:549–59. N Engl J Med. This study was funded by CIBERCV (grant number CB16/11/00451), and Sociedad Española de Arteriosclerosis (SEA 2019). Article Quelle: Fachinformation Rosuvador; Medizinische Chemie: Targets und Arzneistoffe, Steinhilber, Schubert-Zsilavecz, Roth ; The American Journal of Cardiology: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Teilen; Teilen; Teilen; Drucken; Senden; 102 Präparate mit Rosuvastatin. Sign up now for a 30-day trial and save up to 95% at CVS, Kroger, Albertsons, and other pharmacies. JAMA. The mean dose of atorvastatin and rosuvastatin were 50.8 (24.7) mg/day and 21.4 (9.6) mg/day, respectively, corresponding to a medium dose of a high potency statin and they were equivalent with respect to their lipid-lowering efficacy. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Thus 62 recurrences occurred before and 27 after inclusion on the registry. The statin documented in the registry represented the treatment for the follow-up years prior to the recurrence or censoring. Eating grapefruit or drinking grapefruit juice can raise your risk of liver damage while taking Lipitor (atorvastatin). Having too much cholesterol in your blood increases your risk of heart attacks and strokes. It's a good first choice medicine for lowering cholesterol levels when diet and exercise aren't enough. Arterial hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or self-reported use of antihypertensive medication. Eur Heart J. On March 31st, 2019, follow-up data were evaluated and 475 subjects were excluded due to incomplete data, changes in the lipid-lowering drugs, follow-up less than 1 year, or loss to follow-up. Finally, changes in treatment have not been covered during the period of follow-up previous to inclusion in the registry and some subjects have been able to change from atorvastatin to rosuvastatin and vice versa. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. It's available as a generic drug and can be used in combination with other cholesterol lowering drugs. Taking higher doses of Crestor (rosuvastatin). Dyslipemia Registry of Spanish Arteriosclerosis Society. Crestor rated 6.0/10 vs Lipitor rated 4.8/10 in overall patient satisfaction. Multivariable Poisson regression models were fitted including the covariates: age and sex (model 1), diabetes, hypertension, smoking status, body mass index (BMI), non-high-density lipoprotein (non-HDL) cholesterol, HDL cholesterol and ezetimibe use. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.